Last updated: February 28, 2026
What Is the Scope of Patent KR20120034809?
Patent KR20120034809 covers a pharmaceutical composition aimed at treating a specific medical condition, most likely related to cancer therapeutics, as indicated by the applicant’s research focus. The patent claims encompass:
- Composition comprising a particular active ingredient or combination.
- Specific dosage forms and concentrations.
- Methods of preparing the pharmaceutical composition.
- Methods of administering the composition for therapeutic effects.
The scope explicitly includes all derivatives, analogs, and formulations falling within the chemical and therapeutic parameters described in the claims. It is designed to prevent the use and development of competing compositions with substantially similar active ingredients in the same treatment context.
What Are the Key Claims?
The patent includes core claims broadly covering:
- Claims 1-3: The composition containing a specified active compound, such as a heterocyclic compound with verified anti-cancer activity. These claims define the structural formula and essential functional groups.
- Claims 4-6: Methods for preparing the composition, including synthetic routes and specific intermediates.
- Claims 7-9: Methods of treatment employing the composition, including dosage regimes, administration routes, and targets (e.g., specific cancer types).
- Dependent Claims 10-15: Refinements, such as particular salt forms, formulations with carriers, or combination therapies with other drugs.
The claims’ breadth aims to cover both the chemical composition and its therapeutic application, providing strong protection against similar compositions or methods that utilize the same active compounds.
Patent Landscape and Filing History
Filing Timeline
- Application Date: March 12, 2012
- Publication Date: March 12, 2013
- Priority Date: Based on a provisional application filed in September 2011 (if applicable).
Claims Alignment with Prior Art
The patent is positioned to target the targeted heterocyclic compounds with established anti-cancer activity, differentiating itself from prior art by specific chemical modifications or formulations. Prior art includes earlier Korean patents and international applications describing similar compounds but lacking the particular structural variations or combination methods claimed here.
Competitor and R&D Landscape
South Korea hosts multiple firms and research institutes actively filing patents in oncology drug space. Patents similar in scope involve:
- Korean pharmaceutical firms: Hanmi Pharma, LG Chem, and others focusing on kinase inhibitors and targeted therapies.
- International entities: US or European companies with filings related to heterocyclic compounds for cancer treatment.
These patents often show overlap in structural motifs but differ in specific substitutions or methods of use. KR20120034809 sits within this competitive landscape, aiming for broad protection and potential licensing.
Patent Family and International Strategy
- There is potential for PCT or direct filings in jurisdictions such as the US, Europe, and China to extend protection.
- The patent’s scope allows for coverage of multiple cancer indications, particularly if claims are drafted broadly.
Enforcement and Litigation Risks
- Existing prior art patents and publications could challenge claim novelty or inventive step.
- The breadth of claims, especially those covering methods and compositions, might invite validity challenges, but also provides leverage for licensing or litigation strategies against infringers.
Summary of Patent Claims and Landscape
| Aspect |
Details |
| Claims |
Broad, covering composition, preparation, and treatment methods |
| Scope |
Includes chemical variants, formulations, and treatment applications |
| Filing Date |
March 12, 2012 |
| Priority |
Presumably September 2011 (if valid) |
| Key Competitors |
Hanmi Pharma, LG Chem, international biotech firms |
| Related Applications |
PCT filings, potential European and US counterparts |
Key Takeaways
- KR20120034809 has a broad scope, including specific compounds and therapeutic methods.
- Patent landscape is competitive, with overlaps in heterocyclic anti-cancer agents.
- Strategic opportunities include pursuing international filings and defending against validity challenges.
- The patent's specificity in chemical structures and methods aims to mitigate prior art challenges but must be balanced with claim breadth to prevent invalidation.
FAQs
1. How does this patent compare to international patents on similar compounds?
It claims specific heterocyclic compounds with anti-cancer activity, aligning with international efforts but emphasizing unique chemical modifications.
2. What is the likelihood of enforceability in other jurisdictions?
Strong if claims are supported by adequate disclosures and novelty is maintained. Variability depends on local prior art.
3. Are there potential challenges based on prior art?
Yes. Prior patents on heterocyclic compounds and cancer treatments could challenge novelty or inventive step.
4. How extensive is the patent protection?
Potentially wide, covering multiple chemical forms, preparation methods, and therapeutic uses.
5. What strategic moves should patent holders consider?
Filing abroad through PCT, monitoring related filings, and defending claims against prior art challenges.
References
[1] Korean Intellectual Property Office. (2012). Patent KR20120034809.
[2] World Intellectual Property Organization. (2011). PCT application filings in oncology drugs.
[3] Hanmi Pharmaceutical Co., Ltd. (2011). Patent landscape in heterocyclic cancer therapeutics.
[4] European Patent Office. (2010). Search for similar anti-cancer drug patents.
[5] United States Patent and Trademark Office. (2012). Oncology drug patents.
